You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 9,925,150


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,925,150
Title:Polyvinylpyrrolidone for the stabilization of a solid dispersion of the non-crystalline form of rotigotine
Abstract: The present invention relates to a method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6. The present invention also relates to a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine and polyvinylpyrrolidone, wherein the weight ratio of rotigotine to polyvinylpyrrolidone is in a range from about 9:3.5 to about 9:6, a pharmaceutical composition comprising such a solid dispersion, in particular a transdermal therapeutic system, as well as a method for the preparation thereof.
Inventor(s): Wolff; Hans-Michael (Monheim, DE), Arth; Christoph (Monheim, DE), Quere; Luc (Braine-l'Alleud, BE), Muller; Walter (Andernach, DE)
Assignee: LTS Lohmann Therapie-Systeme AG (Andernach, DE) UCB Pharma GmbH (Monheim, DE)
Application Number:13/515,067
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,925,150
Patent Claims: 1. A method for stabilizing rotigotine, the method comprising providing a solid dispersion comprising polyvinylpyrrolidone and a non-crystalline form of rotigotine free base, wherein the weight ratio of rotigotine free base to polyvinylpyrrolidone is about 9:4.

2. A solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine free base and polyvinylpyrrolidone, wherein the weight ratio of rotigotine free base to polyvinylpyrrolidone is about 9:4.

3. The solid dispersion of claim 2, wherein the solubility of rotigotine free base in the dispersing agent is below 1 wt-%.

4. The solid dispersion of claim 2, wherein the dispersing agent comprises at least one silicone pressure sensitive adhesive.

5. The solid dispersion of claim 2, wherein the dispersing agent comprises a mixture of a first silicone pressure sensitive adhesive and a second silicone pressure sensitive adhesive and wherein the solid dispersion has a complex viscosity between 5 and 15 MP.

6. The solid dispersion of claim 2, wherein rotigotine free base and polyvinylpyrrolidone are in a multitude of microreservoirs.

7. A pharmaceutical composition comprising a solid dispersion according to claim 2.

8. A transdermal therapeutic system comprising at least one amine-compatible silicone pressure sensitive adhesive, about 0.1 to about 3.15 mg/cm.sup.2 of rotigotine in the free base form, and polyvinylpyrrolidone, wherein the weight ratio of rotigotine free base to polyvinylpyrrolidone is about 9:4.

9. The transdermal therapeutic system of claim 8, wherein rotigotine free base and polyvinylpyrrolidone are contained in a multitude of microreservoirs.

10. A transdermal therapeutic system comprising a solid dispersion of claim 2.

11. The transdermal therapeutic system of claim 10, comprising 0.1 to about 3.15 mg/cm.sup.2 of rotigotine free base.

12. A method for preparing a transdermal therapeutic system, the method comprising preparing a solid dispersion comprising a dispersing agent and a dispersed phase, said dispersed phase comprising rotigotine free base and polyvinylpyrrolidone, wherein the weight ratio of rotigotine free base to polyvinylpyrrolidone is about 9:4.

13. The method of claim 1, wherein the solid dispersion further comprises a dispersing agent.

14. The method of claim 13, wherein the dispersing agent comprises at least a first adhesive having a complex viscosity between 40 and 250 MP.

15. The method of claim 14, wherein the dispersing agent comprises at least a second adhesive having a complex viscosity between 1 and 10 MP.

16. The method of claim 15, wherein the dispersing agent has a complex viscosity between 5 and 25 MP.

17. The method of claim 13, wherein the dispersing agent comprises at least a first adhesive and a second adhesive and the solid dispersion has a complex viscosity between 5 and 15 MP.

18. The method of claim 13, wherein the dispersing agent comprises at least a first adhesive and a second adhesive and the solid dispersion has a peel adhesion between 3 and 16N/50 mm at a thickness of 50 g/m.sup.2 and/or a peel adhesion between 14 and 26 N/50 mm at a thickness of 150 g/m.sup.2.

19. The method of claim 13, wherein the dispersing agent comprises at least a first adhesive and a second adhesive and the solid dispersion has a static shear adhesion between 20 and 150 min.

20. The solid dispersion of claim 2, wherein the dispersing agent comprises at least a first adhesive having a complex viscosity between 40 and 250 MP.

21. The solid dispersion of claim 2, wherein the dispersing agent comprises at least a second adhesive having a complex viscosity between 1 and 10 MP.

22. The solid dispersion of claim 21, wherein the dispersing agent has a complex viscosity between 5 and 25 MP.

23. The solid dispersion of claim 2, wherein the dispersing agent comprises at least a first adhesive and a second adhesive and the solid dispersion has a complex viscosity between 5 and 15 MP.

24. The solid dispersion of claim 2, wherein the dispersing agent comprises at least a first adhesive and a second adhesive and the solid dispersion has a peel adhesion between 3and 16 N/50 mm at a thickness of 50 g/m.sup.2 and/or a peel adhesion between 14 and 26 N/50 mm at a thickness of 150 g/m.sup.2.

25. The solid dispersion of claim 2, wherein the dispersing agent comprises at least a first adhesive and a second adhesive and the solid dispersion has a static shear adhesion between 20 and 150 min.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.